OUTSTANDING PROCEDURAL PERFORMANCE
The latest study results demonstrate excellent procedural performance.
The Evolut PRO Study is a prospective, multicenter, non-randomized, single-arm study. Primary safety endpoints were all-cause mortality and disabling stroke at 30 days, and the primary efficacy endpoint was percentage of patients with no or trace aortic regurgitation at 30 days.
- Study Status/Duration: 1-year outcomes reported/
- Sample Size: N = 60
- Devices: Evolut PRO TAV
SURTAVI CONTINUED ACCESS STUDY2
Patients underwent attempted TAV implant under the same inclusion and exclusion criteria and trial procedures as the SURTAVI Trial, with no randomization to surgery.
- Study Status/Duration: 30-day outcomes reported/5-year follow-up
- Sample Size: N = 275
- Devices: Evolut R 93%/CoreValve 7%, TAV
See the Medtronic TAVI Clinical Evidence Compendium for additional study results.
Williams, as presented in poster at ACC.18
Van Mieghem N, et al. Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial. Presented at TCT 2017.